These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 26317649

  • 1. Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition.
    Lange L, Hemmerich P, Spänkuch B.
    Oncotarget; 2015 Sep 22; 6(28):25801-14. PubMed ID: 26317649
    [Abstract] [Full Text] [Related]

  • 2. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB, Woo SU, Yim H.
    J Cell Physiol; 2015 Dec 22; 230(12):3057-67. PubMed ID: 25975351
    [Abstract] [Full Text] [Related]

  • 3. Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status.
    Lange L, Keppner-Witter S, Grigat J, Spänkuch B.
    Oncotarget; 2014 Apr 30; 5(8):2263-75. PubMed ID: 24810255
    [Abstract] [Full Text] [Related]

  • 4. Fate of primary cells at the G₁/S boundary after polo-like kinase 1 inhibition by SBE13.
    Keppner S, Proschak E, Schneider G, Spänkuch B.
    Cell Cycle; 2011 Feb 15; 10(4):708-20. PubMed ID: 21301227
    [Abstract] [Full Text] [Related]

  • 5. Biological impact of freezing Plk1 in its inactive conformation in cancer cells.
    Keppner S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spänkuch B.
    Cell Cycle; 2010 Feb 15; 9(4):761-73. PubMed ID: 20139717
    [Abstract] [Full Text] [Related]

  • 6. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD, Ndiaye MA, Huang W, Liu X, Ahmad N.
    Cancer Lett; 2017 Jan 28; 385():179-187. PubMed ID: 27793694
    [Abstract] [Full Text] [Related]

  • 7. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, Wang YQ, Zhang H, Zhan QM, Wang MR.
    Gastroenterology; 2012 Mar 28; 142(3):521-530.e3. PubMed ID: 22108192
    [Abstract] [Full Text] [Related]

  • 8. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K.
    Clin Cancer Res; 2005 Sep 01; 11(17):6382-9. PubMed ID: 16144943
    [Abstract] [Full Text] [Related]

  • 9. Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.
    Shin SB, Woo SU, Chin YW, Jang YJ, Yim H.
    J Cell Physiol; 2017 Oct 01; 232(10):2818-2828. PubMed ID: 27861885
    [Abstract] [Full Text] [Related]

  • 10. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S.
    Oncotarget; 2017 May 09; 8(19):31478-31493. PubMed ID: 28416758
    [Abstract] [Full Text] [Related]

  • 11. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN, Louwen F, Zimmer B, Yuan J.
    Oncotarget; 2015 Mar 30; 6(9):6611-26. PubMed ID: 25483104
    [Abstract] [Full Text] [Related]

  • 12. SBE13 joins the family of Polo-like kinase 1 (Plk1) inhibitors.
    Liu X.
    Cell Cycle; 2010 Feb 01; 9(3):445-6. PubMed ID: 20130451
    [No Abstract] [Full Text] [Related]

  • 13. Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor.
    Wu P, Meng L, Wang H, Zhou J, Xu G, Wang S, Xi L, Chen G, Wang B, Zhu T, Lu Y, Ma D.
    Biochem Biophys Res Commun; 2005 Sep 16; 335(1):36-44. PubMed ID: 16051188
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of Plk1 and Pin1 by 5'-nitro-indirubinoxime suppresses human lung cancer cells.
    Yoon HE, Kim SA, Choi HS, Ahn MY, Yoon JH, Ahn SG.
    Cancer Lett; 2012 Mar 16; 316(1):97-104. PubMed ID: 22115795
    [Abstract] [Full Text] [Related]

  • 15. Equol inhibits proliferation of human gastric carcinoma cells via modulating Akt pathway.
    Yang ZP, Zhao Y, Huang F, Chen J, Yao YH, Li J, Wu XN.
    World J Gastroenterol; 2015 Sep 28; 21(36):10385-99. PubMed ID: 26420965
    [Abstract] [Full Text] [Related]

  • 16. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A, Hugle M, Fulda S.
    Cancer Lett; 2015 Aug 28; 365(1):37-46. PubMed ID: 25917079
    [Abstract] [Full Text] [Related]

  • 17. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, Schulte JH, Temming P.
    Clin Exp Ophthalmol; 2017 Apr 28; 45(3):288-296. PubMed ID: 27647547
    [Abstract] [Full Text] [Related]

  • 18. Modulation of radiation response by histone deacetylase inhibition.
    Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM.
    Int J Radiat Oncol Biol Phys; 2005 May 01; 62(1):223-9. PubMed ID: 15850925
    [Abstract] [Full Text] [Related]

  • 19. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
    Chen F, Zhuo X, Qin T, Guo X, Zhang C, Lai L.
    Chem Biol Drug Des; 2017 May 01; 89(5):732-740. PubMed ID: 27882722
    [Abstract] [Full Text] [Related]

  • 20. Freezing Polo in its sleep: targeting the inactive conformation of Polo-like kinase 1 in cancer cells.
    Eckerdt F.
    Cell Cycle; 2010 Mar 01; 9(5):862. PubMed ID: 20348843
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.